Purification of soluble HLA class I complexes from human serum or plasma deliver high quality immuno peptidomes required for biomarker discovery. Issue 1 (22nd December 2016)

• Record Type: Journal Article
• Authors: Ritz, Danilo; Gloger, Andreas; Neri, Dario; Fugmann, Tim
• Is Part Of: Proteomics. Volume 17:Issue 1/2(2017)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2016-12-22
• Subjects: Antigens -- Biomarker -- Biomedicine -- Body fluids -- HLA peptidomics -- Immunopeptidomics -- sHLA; Proteins -- Separation -- Periodicals; Bioinformatics -- Periodicals; Proteomics -- Periodicals; Genomes -- Periodicals; Molecular genetics -- Periodicals; 572.605
• DOI: 10.1002/pmic.201600364
• Languages: English
• ISSNs: 1615-9853

Abstract

Abstract : Soluble human leukocyte antigen class I (sHLA)‐peptide complexes have been suggested to play a role in the modulation of immune responses and in immune evasion of cancer cells. The set of peptides eluted from sHLA molecules could serve as biomarker for the monitoring of patients with cancer or other conditions. Here, we describe an improved sHLA peptidomics methodology resulting in the identification of 1816 to 2761 unique peptide sequences from triplicate analyses of serum or plasma taken from three healthy donors. More than 90% of the identified peptides were 8–11mers and 74% of these sequences were predicted to bind to cognate HLA alleles, confirming the quality of the resulting immunopeptidomes. In comparison to the HLA peptidome of cultured cells, the plasma‐derived peptides were predicted to have a higher stability in complex with the cognate HLA molecules and mainly derived from proteins of the plasma membrane or from the extracellular space. The sHLA peptidomes can efficiently be characterized by using the new methodology, thus serving as potential source of biomarkers in various pathological conditions.